Ductal Carcinoma In Situ Treatment in Turkey
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is Ductal Carcinoma In situ?
Ductal carcinoma in situ is an extremely early form of breast cancer. When it occurs, the cancer cells are contained within a breast milk duct, and the breast tissue is still free of cancerous cells. A common term for this type of breast cancer is DCIS. This type of breast cancer is sometimes referred to as stage 0, noninvasive, or preinvasive.
DCIS is usually found on a mammogram that is done to screen for breast cancer or to investigate a bulge in the breast. There is a minimal chance that DCIS will become invasive and threaten life. However, it must be evaluated, and treatment options must be considered.
DCIS is often treated with surgery. Other treatments may include hormone therapy or radiation therapy in addition to surgery.
What is the Importance of Timely Treatment?
Ductal Cell Carcinoma in Situ (DCIS) must be treated early to lower the chance of recurrence and spread to other body areas, as well as to stop it from developing into invasive breast cancer. Early detection reduces the psychological and physical effects of more invasive surgeries, increases survival rates, and permits breast-conserving therapy. Patients who receive immediate treatment for DCIS have a better prognosis and a higher quality of life, and their chances of the disease developing into something invasive or life-threatening are significantly decreased.
What are the Common Symptoms of Ductal Carcinoma In situ?
Usually, there are no symptoms associated with ductal carcinoma in situ. DCIS is another name for this early stage of breast cancer.
DCIS can occasionally result in symptoms like:
- A lump in the breast.
- Bloody discharge from the nipples.
Mammography is typically where DCIS is detected. In breast tissue, it manifests as microscopic calcium particles. These are calcifications, which are deposits of calcium.
Causes and Risk Factors of Ductal Carcinoma In Situ
Causes
- A non-malignant breast cancer that starts in the milk ducts is referred to as ductal carcinoma in situ (DCIS). While their exact cause is not known, risk factors are age (typically greater than 50), radiation, family history or genetic defects (e.g., BRCA1/2), hormonal imbalances, and personal history of benign breast disease.
- The risk can also be increased by lifestyle factors such as obesity, alcohol consumption, and lack of exercise, as well as previous reproductive history. Early detection screening is key to the management of DCIS.
Risk Factors
- Age
- Hormonal Factors
- History & Genetics
- Personal History of Breast Conditions
- Radiation Exposure
- Obesity
Connect with our advisor for a PRIORITY response
Latest Research and Technologies in the Treatment of Ductal Carcinoma In Situ in Turkey
Based on the individual circumstances of each patient, ductal carcinoma in situ (DCIS) may be treated surgically in Turkey through a range of methods, including mastectomy and breast-conserving surgery. While mastectomy remains a common choice in most cases, there has been increasing evidence of preference for breast-conserving surgery, as shown by recent studies. Tumor characteristics, patient preferences, and geographical variations in health care all affect the treatment decision. Additionally, radiation is often employed to reduce the likelihood of recurrence. These evolving practices reflect Turkey's commitment to providing patients with personalised, high-quality DCIS treatment.
Treatment options for Ductal Carcinoma In Situ
Lumpectomy: The breast cancer and a portion of the surrounding normal tissue are cut out during a lumpectomy. There is no removal of the rest of the breast tissue. Wide local excision and breast-conserving surgery are alternative names for this procedure. Most patients who have a lumpectomy also undergo radiation therapy.
Mastectomy: The removal of all the breast tissue by operation is called a mastectomy. If you prefer, breast reconstruction to re-form the appearance of the breast may be performed at the same time or later on.
Cost Start From USD 6000 - USD 75000Explore Options
Hormone therapy: Endocrine therapy, also referred to as hormone therapy, involves using drugs that prevent the body from making specific hormones. It is applied in the treatment of breast cancers that are estrogen and progesterone-sensitive.
Cost Start From USD 300 - USD 4000Explore Options
Radiation Therapy: To reduce the risk of recurrence, radiation therapy is often given after surgery for ductal carcinoma in situ (DCIS). It is typically recommended following a lumpectomy, especially if the tumour is large or has high-risk features. High-energy X-rays are employed in the treatment to locate and kill any remaining cancer cells in the breast tissue. Radiation therapy significantly decreases the possibility that DCIS could recur.
- Mammography is the most common screening method for detecting breast calcifications that may indicate DCIS.
- Breast ultrasound is often used together with mammography to evaluate areas of concern further.
- MRI: Provides high-resolution images and helps to determine the extent of DCIS.
- Biopsy: The best test for diagnosing DCIS is a biopsy, in which tissue is removed from the suspicious region to determine whether cancer cells are present.
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services rehabilitation services to support patients through Teleconsulations and online therapy sessions.
- Physical Therapy assists in the recovery of strength, improvement in mobility, and removal of any restrictions after surgery (e.g., mastectomy or lumpectomy).
- Lymphedema Management: Physical therapists can attempt to reduce arm or breast swelling in patients receiving radiation therapy or surgery.
- Depending on the severity of the condition, your healthcare professional may prescribe medicine to help control your symptoms and support the treatment plan.
Instantly Connect with our Specialists
Hospitals for Ductal Carcinoma In Situ in Turkey
Ekol
Izmir, Turkey
Ekol Hospitals, located in Izmir, Turkey, offers a revolutionary approach to healthcare with its unique integrated model. The hospital is made up of two general hospitals and three specialized medical centers, boasting a total of 250 beds. With a team of 130 highly qualified surgeons and over 500 healthcare professionals, Ekol Hospitals is equipped with state-of-the-art technology to provide exceptional care. The hospital’s Health and Rehabilitation Centre, which was acquired from a hotel space, ensures a comfortable and convenient environment for patients, offering both excellent medical services and access to local attractions. Ekol Hospitals proudly serves a diverse international clientele, with medical staff fluent in English, German, French, and Turkish, and offers competitively priced treatment options. Accredited by respected global agencies, Ekol Hospitals is committed to delivering top-tier healthcare to patients from around the world.
Anadolu Medical Center
Kocaeli, Turkey
Anadolu Medical Center located in Kocaeli, Turkey is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:
- The Medical Center is present over an area of 188.000 square meters. This is inclusive of the indoor area which is 50 thousand square meters.
- Let us also have a look at some of the important infrastructure pointers of this hospital.
- Bed capacity of 201
- Outpatient Clinic at Ata?ehir
- Bone Marrow Transplantation Center that opened its doors in June 2010
- Developed and using latest technologies such as IMRT and Cyberknife
- Multidisciplinary care
- An OECI-designated clinical cancer centre
I.A.U VM Medical Park Florya Hospital
Istanbul, Turkey
I.A.U VM Medical Park Florya Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
- Situated on an area of 51.000 m2
- Capacity of 300 beds
- 13 Operating rooms
- 92 Polyclinics
- Emergency Unit
- Intensive care Unit
- Parking lots
- Places of worship
- Rooms designed according to different needs offer the comfort of a 5-star hotel
- Special services are provided in all rooms, from television with domestic and foreign channels to internet service, from patient-specific diet menu to newspaper and magazine service
- Cafe/Restaurant with delicious menu
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose Turkey for Duct Carcinoma In Situ Treatment?
Turkey is an excellent destination for treating Duct Carcinoma In Situ (DCIS) due to its world-class medical infrastructure, highly trained medical professionals, and access to the latest technologies. The country offers comprehensive care tailored to each patient's requirements, such as radiation therapy, surgery, and targeted therapies. Turkey is also a favoured destination for high-value care because the cost of medical care is often lower compared to other countries.
Frequently Asked Questions
Yes, mammography can often detect ductal carcinoma in situ (DCIS). DCIS usually appears as microcalcifications, microscopic calcium deposits that appear as white specks on X-rays. Microcalcifications can also occur with benign conditions, but when they occur in specific patterns, they can be a marker for DCIS. Mammograms are a key early detection method for DCIS, often before symptoms develop.
In Turkey, a biopsy is the gold standard for diagnosing ductal carcinoma in situ (DCIS). While mammograms and other imaging tests can identify problematic spots, a biopsy is necessary to collect a tissue sample for microscopic analysis. Doctors can use this to effectively diagnose DCIS, evaluate its features, and choose the best course of treatment.
In Turkey, ductal carcinoma in situ (DCIS) often needs surgery, although this depends on the individual case. Based on the size, location, and other features of the DCIS, the most frequent surgical options are mastectomy (breast removal) or lumpectomy (tumour removal).
Surgery is not always needed for DCIS, especially if the issue is detected early and can be treated with hormone therapy or radiation. After consultation with the medical team, the choice is made according to the patient's condition and personal preferences.
Mastectomy can be suggested for Ductal Carcinoma In Situ (DCIS) in Turkey if the DCIS is large or widespread or if it occurs in several locations within the breast so that breast-conserving surgery such as lumpectomy is not as effective. It can also be suggested if the patient is at high risk of recurrence or if prior surgery has not worked to remove the cancer.
Radiation therapy is often recommended in Turkey’s healthcare environments for ductal carcinoma in situ (DCIS), particularly after a lumpectomy. It targets any remaining breast cancer cells, reducing the risk of recurrence. However, radiation therapy is not required for all DCIS patients. Tumor size, margins, grade, and other risk factors affect the decision.
In Turkish patients, ductal carcinoma in situ (DCIS) may recur after treatment; the risk is low if proper treatment is undertaken. The opposite or the same breast (local recurrence) can suffer from recurrence. Several factors, such as the grade of DCIS, the surgical margins, the application of radiation therapy, and the patient's overall condition, can influence the risk of recurrence. Imaging tests, monitoring, and follow-up treatment are essential in detecting early recurrence.
In Turkey, women with Duct Carcinoma In Situ (DCIS), which is a non-invasive form of breast cancer, generally have good survival rates. For the majority of women, favourable outcomes are achievable with early diagnosis and favourable treatment like hormone therapy, radiation, and surgery. Better survival rates among women with DCIS are due to Turkey's advanced medical facilities and access to the latest cancer treatments.
Yes, you can get a second opinion on Ductal Cell Carcinoma treatment in Turkey through MediGence. With MediGence, you can connect with highly experienced professionals from top Turkish hospitals who can provide additional information regarding your diagnosis and treatment options. The platform facilitates easy access to professional help so you can make informed healthcare choices and receive the best care possible.
To find a certified cancer specialist, search MediGence’s website, which offers a list of top-class and internationally trained oncologists from Turkey's best hospitals. Through MediGence, you can search the profiles of specialists, check their credentials, reviews, and experience, and book online consultations. To get the best care for your condition, the website also assists you in finding the best hospitals and provides personalised assistance for your health requirements.